These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37752685)

  • 1. SYNAPSES. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: post-hoc analysis of the Spanish study population.
    Kulisevsky J; Esquivel A; Freire-Álvarez E; Gómez-Esteban JC; Legarda-Ramírez I; Avilés A; Mata-Álvarez-Santullano M
    Rev Neurol; 2023 Oct; 77(s02):1-12. PubMed ID: 37752685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
    ; Bergmans B; Bourgeois P; Cras P; Dethy S; De Klippel N; Franco G; Garraux G; Geens K; Jacquerye P; Jeanjean A; Supiot F; Van der Linden C; Krygier C
    Acta Neurol Belg; 2023 Jun; 123(3):939-947. PubMed ID: 36201116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world data of a German Parkinson's disease population: effectiveness and safety of safinamide in routine clinical practice.
    Jost WH; Gluth I; Lück JC; Lopes OIFDC;
    Curr Med Res Opin; 2023 Dec; 39(12):1621-1628. PubMed ID: 37421634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study.
    Nishikawa N; Hatano T; Nishioka K; Ueno SI; Saiki S; Nakamura R; Yoritaka A; Ogawa T; Shimo Y; Sako W; Shimura H; Furukawa Y; Kamei T; Ishida T; Hattori N;
    J Neurol Sci; 2024 Jun; 461():123051. PubMed ID: 38788287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial.
    Abbruzzese G; Kulisevsky J; Bergmans B; Gomez-Esteban JC; Kägi G; Raw J; Stefani A; Warnecke T; Jost WH;
    J Parkinsons Dis; 2021; 11(1):187-198. PubMed ID: 33104040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
    Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
    Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.
    Bovenzi R; Liguori C; Canesi M; D'Amelio M; De Pandis MF; Marini C; Monge A; Padovani A; Tessitore A; Stefani A; Zappia M;
    Neurol Sci; 2024 Feb; 45(2):573-583. PubMed ID: 37684511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
    Nomoto M; Ishida T; Koebis M; Kamei T; Suzuki I; Hattori N; Tsuboi Y
    J Neurol Sci; 2022 Mar; 434():120083. PubMed ID: 35007919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
    Abdelalem Aziz Ahmed M
    F1000Res; 2019; 8():2078. PubMed ID: 32431802
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
    Tsuboi Y; Koebis M; Kogo Y; Ishida T; Suzuki I; Nomoto M; Hattori N
    J Neurol Sci; 2021 Oct; 429():118070. PubMed ID: 34509801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
    Morales-Casado MI; García-Meléndez DD; Diezma-Martín A; López-Ariztegui N
    Rev Neurol; 2023 Oct; 77(S03):S1-S7. PubMed ID: 37882094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.